Inhalation of hydrogen gas elevates urinary 8-hydroxy-2′-deoxyguanine in Parkinson’s disease.
Masaaki Hirayama, Mikako Ito, Tomomi Minato, Asako Yoritaka, Tyler W LeBaron, Kinji Ohno · Medical gas research · 2018
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 20 patients with an 8-week washout period in 20 patients with PD, although the researchers did not observe any beneficial effect of hydrogen in the authors' short trial, the researchers propose that the increased 8-OHdG and other reported stress responses from hydrogen may indicate that its beneficial effects are partly or largely mediated by hormetic mechanisms. These findings add human evidence that helps define the outcomes that did and did not change with molecular hydrogen in this study.
What the Findings Mean
H2HUBB reviewed how inhaled hydrogen gas affected the outcomes measured in 20 patients with an 8-week washout period in 20 patients with PD. Although the researchers did not observe any beneficial effect of hydrogen in the authors' short trial, the researchers propose that the increased 8-OHdG and other reported stress responses from hydrogen may indicate that its beneficial effects are partly or largely mediated by hormetic mechanisms.
What the Researchers Studied
The researchers studied 20 patients with an 8-week washout period in 20 patients with PD. The study used a randomized, double-blind, placebo-controlled, crossover human clinical trial. The comparison condition was placebo.
What Effects Did Molecular Hydrogen Have?
1.4% inhaled H₂ concentration; reported treatment duration: 10 minutes. Although the researchers did not observe any beneficial effect of hydrogen in the authors' short trial, the researchers propose that the increased 8-OHdG and other reported stress responses from hydrogen may indicate that its beneficial effects are partly or largely mediated by hormetic mechanisms. Increases of oxidative stress by hydrogen have been previously reported, along with its ability to activate the Nrf2, NF-κB pathways, and heat shock responses.
Why These Findings Matter
This publication adds useful evidence about where molecular hydrogen did and did not change the measured outcomes, helping define the larger therapeutic evidence base.
How Strong Is This Evidence?
This is human clinical evidence from a randomized, double-blind, placebo-controlled, crossover human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 20 patients with an 8-week washout period in 20 patients with PD. The reported sample size was 20. The study used a randomized, double-blind, placebo-controlled, crossover human clinical trial. The hydrogen delivery method was inhaled hydrogen gas. The reported hydrogen concentration was 1.4% inhaled H₂ concentration. The reported treatment duration was 10 minutes.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.